share_log

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K：重大事件
美股SEC公告 ·  08/23 16:42

Moomoo AI 已提取核心信息

Mangoceuticals, Inc., a Texas-based pharmaceutical company, has successfully completed the sale of an additional 500 shares of Series B Convertible Preferred Stock to an institutional accredited investor for $500,000 on August 22, 2024. This transaction is part of a partial fourth closing under a Securities Purchase Agreement (SPA) that was previously amended in April 2024. The shares were sold at a 10% discount to their stated value of $1,100 per share. The company's stockholders had approved this issuance at the Annual Meeting on June 17, 2024, in compliance with Nasdaq Listing Rule 5635(d). The rights and preferences of the Series B Preferred Stock have been detailed in prior reports filed with the SEC. The issuance was exempt from registration under the Securities Act of 1933, as it was not a public offering and the purchaser is an accredited investor. Additionally, on the same day, Mangoceuticals' Board of Directors approved an increase in the monthly car allowance for CEO Jacob Cohen from $1,500 to $2,500.
Mangoceuticals, Inc., a Texas-based pharmaceutical company, has successfully completed the sale of an additional 500 shares of Series B Convertible Preferred Stock to an institutional accredited investor for $500,000 on August 22, 2024. This transaction is part of a partial fourth closing under a Securities Purchase Agreement (SPA) that was previously amended in April 2024. The shares were sold at a 10% discount to their stated value of $1,100 per share. The company's stockholders had approved this issuance at the Annual Meeting on June 17, 2024, in compliance with Nasdaq Listing Rule 5635(d). The rights and preferences of the Series B Preferred Stock have been detailed in prior reports filed with the SEC. The issuance was exempt from registration under the Securities Act of 1933, as it was not a public offering and the purchaser is an accredited investor. Additionally, on the same day, Mangoceuticals' Board of Directors approved an increase in the monthly car allowance for CEO Jacob Cohen from $1,500 to $2,500.
总部位于德克萨斯州的药品公司Mangoceuticals成功完成了向一家机构认可投资者出售额外500股B系列可转换优先股，以50万美元的价格于2024年8月22日。该交易是在此前已于2024年4月修改过的证券购买协议（SPA）的部分第四次结案中的一部分。这些股份以每股1100美元的面值的10%折扣出售。公司股东在2024年6月17日的年度股东大会上批准了此次发行，以符合纳斯达克上市规则5635(d)。B系列优先股的权利和偏好已在之前向SEC提交的报告中详细说明。由于这不是一次公开发行，购买者是一家认可投资者，该发行免于根据1933年证券法注册。此外，同一天，Mangoceuticals的董事会批准了将CEO Jacob Cohen的每月汽车津贴从1500美元增加到2500美元。
总部位于德克萨斯州的药品公司Mangoceuticals成功完成了向一家机构认可投资者出售额外500股B系列可转换优先股，以50万美元的价格于2024年8月22日。该交易是在此前已于2024年4月修改过的证券购买协议（SPA）的部分第四次结案中的一部分。这些股份以每股1100美元的面值的10%折扣出售。公司股东在2024年6月17日的年度股东大会上批准了此次发行，以符合纳斯达克上市规则5635(d)。B系列优先股的权利和偏好已在之前向SEC提交的报告中详细说明。由于这不是一次公开发行，购买者是一家认可投资者，该发行免于根据1933年证券法注册。此外，同一天，Mangoceuticals的董事会批准了将CEO Jacob Cohen的每月汽车津贴从1500美元增加到2500美元。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间